We are monitoring the impact of COVID-19 & Recession alarm on APAC Ophthalmic Drugs Market Get in touch with us for detailed analysis Know More

Know More

Share on

Asia Pacific Ophthalmic Drugs Market Research Report - Segmented By Therapeutic Class, Product Type, Distribution Channel, Disease Indication, Dosage Form, Technology and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 5303
Pages: 145

APAC Ophthalmic Drugs Market Size (2022 to 2027)

The size of the Asia Pacific Ophthalmic Drugs market was valued at around USD 7.10 billion in 2022. It is expected to grow at a CAGR of 6.9% and be worth USD 9.91 billion by 2027. It captures 20% of the global market share.

The growth of the APAC ophthalmic drugs market is majorly driven by the rising number of individuals suffering from glaucoma and tremendous innovation and funding in developing combination therapies. In addition, the ocular pharmaceuticals market is driven by increased FDA approvals, which raises medication approvals and increases surgeries in the ophthalmology industry due to the high prevalence of reactive defects. In addition, the market is expanding as the population ages, the incidence of eye disorders rises, healthcare spending rises, and the use of minimally invasive surgeries rises.

As the prevalence of eye problems develops, the global need for ophthalmic medications is growing. Eye diseases have already emerged as potential threats to people’s visual experience in many developed and developing countries. As the prevalence of diabetes has increased in many areas, diabetes medicines have been introduced. Glaucoma has been on the public health agenda for years due to difficulties recognizing it early and the need for long-term treatment.

However, the development of new pharmaceuticals is impeded by undesirable side effects and long gestation periods, limiting market expansion. Two issues limit the industry’s growth, well-known pharmaceuticals falling off-patent and big players being hampered by the time it takes for new drugs to join the market. In addition, risks associated with ocular disorders and the lack of public understanding of ophthalmology threaten the market.

This research report on the Asia Pacific ophthalmic drugs market has been segmented and sub-segmented into the following categories:

By Therapeutic Class: 

  • Anti-inflammatory Drugs
  • Anti-infective Drugs
  • Anti-glaucoma Drugs
  • Anti-allergy Drugs
  • Anti-VEGF Agents
  • Others

By Product Type: 

  • Prescription Drugs
  • Over-the-Counter Drugs 

By Distribution Channel: 

  • Hospital Pharmacies
  • Online Pharmacies
  • Independent Pharmacies
  • Drug Stores 

By Disease Indications: 

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation
  • Retinal Disorders
  • Allergy
  • Uveitis
  • Others  

By Dosage Form: 

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Other Ophthalmic Drug Forms       

By Technology: 

  • Biologics
  • Cell Therapy
  • Gene Therapy
  • Drug Delivery
  • Small molecule
  • Others 

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

The Asia Pacific is the fastest-growing market. As a result, the ophthalmic drugs market is expected to witness significant growth during the forecast period. The market growth is attributed to the expanding patient population suffering from vision disorders, advanced medications for treating ophthalmic diseases and improving the healthcare sector. The growth contributors in the region are China, India, China, Japan, and Australia.

China held the largest share of the ophthalmic drugs market and is anticipated to record a promising share during the forecast period. The market growth is fuelled by the availability of advanced Medical infrastructure and increased health insurance coverage, and high healthcare spending.

Government measures to fund eye care research are also expected to fuel the Australian ophthalmic medicines market during the projected period. The government’s financing would go toward various ophthalmic research initiatives to develop advanced medicines to help Australia’s ophthalmology drugs market growth. In Japan, there are a large number of people aged 65 and up. Glaucoma is also more common as people get older. As a result, increased glaucoma prevalence and rising healthcare spending are propelling the market growth.

On the other hand, according to the statement of clinical and experimental vision and eye research, the ophthalmic drugs market in India is predicted to be one of the three top pharmaceutical markets. As per the National health policy, Glaucoma is the leading cause of blindness in India, with at least 12 million people affected and 1.2 million blinded over the recent period.

KEY MARKET PLAYERS:

A few promising companies in the Asia-Pacific ophthalmic drugs market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.

1. Introduction           

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions                

2. Research Methodology                     

                2.1 Introduction         

                2.2 Research Phases

          2.2.1 Secondary Research           

          2.2.2 Primary Research 

          2.2.3 Econometric Modelling      

          2.2.4 Expert Validation  

                2.3 Analysis Design   

                2.4 Study Timeline    

3. Overview                 

                3.1 Executive Summary                

                3.2 Key Inferences   

                3.3 Epidemology        

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)              

                4.1 Market Drivers    

                4.2 Market Restraints                    

                4.3 Key Challenges   

                4.4 Current Opportunities in the Market        

5. Market Segmentation  

                5.1 Therapeutic Class                     

          5.1.1 Introduction           

          5.1.2 Anti-inflammatory Drugs  

    5.1.2.1 Nonsteroidal Anti-inflammatory Drugs

    5.1.2.2 Steroids

          5.1.3 Anti-infective Drugs            

    5.1.3.1 Anti-fungal Drugs

    5.1.3.2 Anti-bacterial Drugs

    5.1.3.3 Others

          5.1.4 Anti-glaucoma Drugs          

    5.1.4.1 Alpha Agonist

    5.1.4.2 Beta Blockers

    5.1.4.3 Prostaglandin Analogs

    5.1.4.4 Combined Medication

    5.1.4.5 Others

          5.1.5 Anti-allergy Drugs

          5.1.6 Anti-VEGF Agents

          5.1.7 Others      

          5.1.8 Y-o-Y Growth Analysis, By Therapeutic Class            

          5.1.9 Market Attractiveness Analysis, By Therapeutic Class          

          5.1.10 Market Share Analysis, By Therapeutic Class         

                5.2 Product Type       

          5.2.1 Introduction           

          5.2.2 Prescription Drugs               

          5.2.3 Over-the-Counter Drugs   

          5.2.4 Y-o-Y Growth Analysis, By Product Type    

          5.2.5 Market Attractiveness Analysis, By Product Type  

          5.2.6 Market Share Analysis, By Product Type    

                5.3 Distribution Channel         

          5.3.1 Introduction           

          5.3.2 Hospital Pharmacies            

          5.3.3 Online  Pharmacies              

          5.3.4 Independent Pharmacies & Drug Stores    

          5.3.5 Y-o-Y Growth Analysis, By Distribution Channel      

          5.3.6 Market Attractiveness Analysis, By Distribution Channel    

          5.3.7  Market Share Analysis, By Distribution Channel     

                5.4 Disease Indications                 

          5.4.1 Introduction           

          5.4.2 Dry Eye     

          5.4.3 Glaucoma

          5.4.4 Infection/Inflammation     

          5.4.5 Retinal Disorders  

    5.4.5.1 Wet Age-related Macular Degeneration

    5.4.5.2 Dry Age-related Macular Degeneration

    5.4.5.3 Diabetic Retinopathy

    5.4.5.4 Others

          5.4.6 Allergy      

          5.4.7 Uveitis      

          5.4.8 Others      

          5.4.9 Y-o-Y Growth Analysis, By Disease Indications         

          5.4.10 Market Attractiveness Analysis, By Disease Indications    

          5.4.11 Market Share Analysis, By Disease Indications      

                5.5 Dosage Form       

          5.5.1 Introduction           

          5.5.2 Liquid Ophthalmic Drug Forms        

          5.5.3 Solid Ophthalmic Drug Forms          

          5.5.4 Semisolid Ophthalmic Drug Forms

          5.5.5 Multicompartment Drug Delivery Systems               

          5.5.6 Other Ophthalmic Drug Forms        

          5.5.7 Y-o-Y Growth Analysis, By Dosage Form     

          5.5.8  Market Attractiveness Analysis, By Dosage Form  

          5.5.9  Market Share Analysis, By Dosage Form   

                5.6 Technology                 

          5.6.1 Introduction           

          5.6.2 Biologics   

          5.6.3 Cell Therapy           

          5.6.4 Gene Therapy       

          5.6.5 Drug Delivery         

          5.6.6 Small molecule      

          5.6.7 Others      

          5.6.8 Y-o-Y Growth Analysis, By Technology        

          5.6.9 Market Attractiveness Analysis, By Technology      

          5.6.10 Market Share Analysis, By Technology     

6. Geographical Analysis  

                6.1 Introduction         

          6.1.1 Regional Trends    

          6.1.2 Impact Analysis     

          6.1.3 Y-o-Y Growth Analysis        

    6.1.3.1 By Geographical Area

    6.1.3.2 By Therapeutic Class

    6.1.3.3 By Product Type

    6.1.3.4 By Distribution Channel

    6.1.3.5 By Disease Indication

    6.1.3.6 By Dosage Form

    6.1.3.7 By Technology

          6.1.4  Market Attractiveness Analysis     

    6.1.4.1 By Geographical Area

    6.1.4.2 By Therapeutic Class

    6.1.4.3 By Product Type

    6.1.4.4 By Distribution Channel

    6.1.4.5 By Disease Indication

    6.1.4.6 By Dosage Form

    6.1.4.7 By Technology

          6.1.5  Market Share Analysis      

    6.1.5.1 By Geographical Area

    6.1.5.2 By Therapeutic Class

    6.1.5.3 By Product Type

    6.1.5.4 By Distribution Channel

    6.1.5.5 By Disease Indication

    6.1.5.6 By Dosage Form

    6.1.5.7 By Technology

                6.2 China       

                6.3 India        

                6.4 Japan      

                6.5 South Korea         

                6.6 Australia

7. Strategic Analysis                 

                7.1 PESTLE analysis   

          7.1.1 Political     

          7.1.2 Economic 

          7.1.3 Social         

          7.1.4 Technological         

          7.1.5 Legal          

          7.1.6 Environmental       

                7.2 Porter’s Five analysis        

          7.2.1 Bargaining Power of Suppliers        

          7.2.2 Bargaining Power of Consumers    

          7.2.3 Threat of New Entrants     

          7.2.4 Threat of Substitute Products and Services              

          7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                  

                8.1 Abbott Medical Optics, Inc.                 

          8.1.1 Overview 

          8.1.2 Product Analysis   

          8.1.3 Financial analysis  

          8.1.4 Recent Developments       

          8.1.5 SWOT analysis       

          8.1.6 Analyst View          

                8.2 Carl-Zeiss AG       

                8.3 Ellex Medical Lasers Ltd. 

                8.4 Essilor International S.A. 

                8.5 Hoya Corporation                    

                8.6 Insight Vision Inc.                     

                8.7 Nidek Co.Ltd        

                8.8 Novagali Pharma S A         

                8.9 Topcon Corporation          

                8.10 Ziemer Ophthalmic Systems AG.                    

9. Competitive Landscape                     

                9.1 Market share analysis      

                9.2 Merger and Acquisition Analysis 

                9.3 Agreements, collaborations and Joint Ventures   

                9.4 New Product Launches   

10. Market Outlook and Investment Opportunities                   

Appendix                     

                a) List of Tables                

                b) List of Figures        

  1. Asia Pacific Ophthalmic Drugs Market, By Disease Indication, From 2022 - 2027 (USD Billion)
  2. Asia Pacific Dry Eye Market, By Region, From 2022 - 2027 (USD Billion)
  3. Asia Pacific Glaucoma Market, By Region, From 2022 - 2027 (USD Billion)
  4. Asia Pacific Infection/Inflammation Market, By Region, From 2022 - 2027 (USD Billion)
  5. Asia Pacific Retinal Disorders Market, By Region, From 2022 - 2027 (USD Billion)
  6. Asia Pacific Allergy Market, By Region, From 2022 - 2027 (USD Billion)
  7. Asia Pacific Uveitis Market, By Region, From 2022 - 2027 (USD Billion)
  8. Asia Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
  9. Asia Pacific Ophthalmic Drugs Market, By Therapeutic Class, From 2022 - 2027 (USD Billion)
  10. Asia Pacific Anti-inflammatory Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  11. Asia Pacific Anti-infective Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  12. Asia Pacific Anti-glaucoma Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  13. Asia Pacific Anti-allergy Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  14. Asia Pacific Anti-VEGF Agents Market, By Region, From 2022 - 2027 (USD Billion)
  15. Asia Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
  16. Asia Pacific Ophthalmic Drugs Market, By Product Type, From 2022 - 2027 (USD Billion)
  17. Asia Pacific Prescription Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  18. Asia Pacific Over-the-Counter Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  19. Asia Pacific Ophthalmic Drugs Market, By Distribution Channel, From 2022 - 2027 (USD Billion)
  20. Asia Pacific Hospital Pharmacies Market, By Region, From 2022 - 2027 (USD Billion)
  21. Asia Pacific Online Pharmacies Market, By Region, From 2022 - 2027 (USD Billion)
  22. Asia Pacific Independent Pharmacies & Drug Stores Market, By Region, From 2022 - 2027 (USD Billion)
  23. Asia Pacific Ophthalmic Drugs Market, By Dosage Form, From 2022 - 2027 (USD Billion)
  24. Asia Pacific Liquid Ophthalmic Drug Forms Market, By Region, From 2022 - 2027 (USD Billion)
  25. Asia Pacific Solid Ophthalmic Drug Forms Market, By Region, From 2022 - 2027 (USD Billion)
  26. Asia Pacific Semisolid Ophthalmic Drug Forms Market, By Region, From 2022 - 2027 (USD Billion)
  27. Asia Pacific Multicompartment Drug Delivery Systems Market, By Region, From 2022 - 2027 (USD Billion)
  28. Asia Pacific Other Ophthalmic Drug Forms Market, By Region, From 2022 - 2027 (USD Billion)
  29. Asia Pacific Ophthalmic Drugs Market, By Technology, From 2022 - 2027 (USD Billion)
  30. Asia Pacific Biologics Market, By Region, From 2022 - 2027 (USD Billion)
  31. Asia Pacific Cell Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  32. Asia Pacific Gene Therapy Market, By Region, From 2022 - 2027 (USD Billion)
  33. Asia Pacific Drug Delivery Market, By Region, From 2022 - 2027 (USD Billion)
  34. Asia Pacific Small molecule Market, By Region, From 2022 - 2027 (USD Billion)
  35. Asia Pacific Others Market, By Region, From 2022 - 2027 (USD Billion)
  36. Japan Ophthalmic Drugs Market, By Disease Indication, From 2022 - 2027 (USD Billion)
  37. Japan Ophthalmic Drugs Market, By Therapeutic Class, From 2022 - 2027 (USD Billion)
  38. Japan Ophthalmic Drugs Market, By Product Type, From 2022 - 2027 (USD Billion)
  39. Japan Ophthalmic Drugs Market, By Distribution Channel, From 2022 - 2027 (USD Billion)
  40. Japan Ophthalmic Drugs Market, By Dosage Form, From 2022 - 2027 (USD Billion)
  41. Japan Ophthalmic Drugs Market, By Technology, From 2022 - 2027 (USD Billion)
  42. China Ophthalmic Drugs Market, By Disease Indication, From 2022 - 2027 (USD Billion)
  43. China Ophthalmic Drugs Market, By Therapeutic Class, From 2022 - 2027 (USD Billion)
  44. China Ophthalmic Drugs Market, By Product Type, From 2022 - 2027 (USD Billion)
  45. China Ophthalmic Drugs Market, By Distribution Channel, From 2022 - 2027 (USD Billion)
  46. China Ophthalmic Drugs Market, By Dosage Form, From 2022 - 2027 (USD Billion)
  47. China Ophthalmic Drugs Market, By Technology, From 2022 - 2027 (USD Billion)
  48. India Ophthalmic Drugs Market, By Disease Indication, From 2022 - 2027 (USD Billion)
  49. India Ophthalmic Drugs Market, By Therapeutic Class, From 2022 - 2027 (USD Billion)
  50. India Ophthalmic Drugs Market, By Product Type, From 2022 - 2027 (USD Billion)
  51. India Ophthalmic Drugs Market, By Distribution Channel, From 2022 - 2027 (USD Billion)
  52. India Ophthalmic Drugs Market, By Dosage Form, From 2022 - 2027 (USD Billion)
  53. India Ophthalmic Drugs Market, By Technology, From 2022 - 2027 (USD Billion)
  54. Australia Ophthalmic Drugs Market, By Disease Indication, From 2022 - 2027 (USD Billion)
  55. Australia Ophthalmic Drugs Market, By Therapeutic Class, From 2022 - 2027 (USD Billion)
  56. Australia Ophthalmic Drugs Market, By Product Type, From 2022 - 2027 (USD Billion)
  57. Australia Ophthalmic Drugs Market, By Distribution Channel, From 2022 - 2027 (USD Billion)
  58. Australia Ophthalmic Drugs Market, By Dosage Form, From 2022 - 2027 (USD Billion)
  59. Australia Ophthalmic Drugs Market, By Technology, From 2022 - 2027 (USD Billion)
  60. South Korea Ophthalmic Drugs Market, By Disease Indication, From 2022 - 2027 (USD Billion)
  61. South Korea Ophthalmic Drugs Market, By Therapeutic Class, From 2022 - 2027 (USD Billion)
  62. South Korea Ophthalmic Drugs Market, By Product Type, From 2022 - 2027 (USD Billion)
  63. South Korea Ophthalmic Drugs Market, By Distribution Channel, From 2022 - 2027 (USD Billion)
  64. South Korea Ophthalmic Drugs Market, By Dosage Form, From 2022 - 2027 (USD Billion)
  65. South Korea Ophthalmic Drugs Market, By Technology, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample